


Scientists report positive immune response against mpox using a COVID-19 vaccine

March 4 2024



MVA-specific humoral and cellular responses in COH04S1-vaccinated healthy adults. a COH04S1 schedule and dosing in healthy adults. Large circles indicate time of vaccination. MVA-specific humoral responses. MVA-specific IgG endpoint titers (b), and neutralizing antibodies (NAb) (c) were measured by ELISA and neutralization assay in subjects before vaccination, post-prime vaccination, and at one- and five-months post-booster vaccination with COH04S1 at dose-level (DL) 1 (DL1/DL1 [lavender circles] and DL1/placebo/DL1 [upward purple triangles]), DL2 (DL2/DL2 [downward pink

triangles]), and DL3 (DL3/DL3 [green squares]) (n = 5 subjects/group). Placebo controls (n = 4 subjects [gray diamonds]) were included. c MVA-specific cellular responses. MVA-specific CD8+ and CD4 + T cells co-expressing CD107 (blue circles and downward pink triangles, respectively) or CD69 (upward purple triangles and green squares, respectively) markers were measured by intracellular IFN γ staining in subjects described in b-c. Box plots show 25th–75th percentiles, lines indicate medians, whiskers go from minimum to maximum values. Two-way ANOVA followed by Tukey’s multiple comparison test was used in (b, c) after log transformation. Two-tailed Wilcoxon paired T test was used in (d). P values

Citation: Scientists report positive immune response against mpox using a COVID-19 vaccine (2024, March 4) retrieved 27 April 2024 from <https://medicalxpress.com/news/2024-03-scientists-positive-immune-response-mpox.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.